Keryx Biopharmaceuticals, Inc. News Release

Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress

Mon, 21 May 2012 12:30:23 GMT

NEW YORK, May 21, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that an abstract highlighting the dose related increases in iron storage parameters as observed in prior clinical trials of Zerenex™ (ferric citrate), has been accepted for poster presentation at the upcoming 49th ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) Congress, taking place May 24-27, 2012, in Paris, France. The following poster will be presented on Saturday, May 26, 2012, from 9:30am to 10:45am local time: A Meta-Analysis of Ferric Citrate for Hyperphosphatemia: The Effects of an Oral Iron-Containing Phosphate Binder on ...

Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference

Thu, 10 May 2012 12:31:08 GMT

Presentation Scheduled for Tuesday, May 15 at 12:00 noon PT NEW YORK, May 10, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 11th Annual JMP Securities Research Conference, which will be held at the Ritz Carlton Hotel in San Francisco. Mr. Bentsur's presentation is scheduled to take place on Tuesday, May 15, 2012 at 12:00 noon Pacific Time (3:00 p.m. Eastern). A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be ava...

Keryx Biopharmaceuticals Announces Upcoming Poster Presentations of Zerenex(TM) (ferric citrate) at National Kidney Foundation (NKF) 2012 Spring Clinical Meetings

Wed, 09 May 2012 12:04:28 GMT

NEW YORK, May 9, 2012 /PRNewswire via COMTEX/ --Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from prior clinical trials of Zerenex(TM) (ferric citrate), have been accepted for poster presentation at the upcoming National Kidney Foundation (NKF) 2012 Spring Clinical Meetings, taking place May 9-13, 2012, in Washington, DC. The following posters will be presented by DaVita Clinical Research (DCR). The research was commissioned by Keryx and performed by DCR for presentation at the NKF meeting on Thursday, May 10, 2012, from 6:00pm-7:30pm: Reduced Use of Erythropoiesis-Stimulating A...

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results

Tue, 08 May 2012 20:54:08 GMT

Keryx to Host Investor Conference Call on Wednesday, May 9, 2012 at 8:30am EDT NEW YORK, May 8, 2012 /PRNewswire via COMTEX/ --Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2012. At March 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $31.0 million, as compared to $39.5 million at December 31, 2011. The net loss for the first quarter ended March 31, 2012 was $9.1 million, or $0.1...

Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results

Mon, 07 May 2012 20:33:24 GMT

Investor Conference Call to be held Wednesday, May 9, 2012 at 8:30am EDT NEW YORK, May 7, 2012 /PRNewswire via COMTEX/ --Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Wednesday, May 9, 2012 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2012 and a business outlook for the remainder of 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host the call. In order to participate in the conference call, please call 1-877-869-3847 (U.S...

Keryx Biopharmaceuticals Announces Reversion of KRX-0401 (Perifosine) License Rights to Aeterna Zentaris

Mon, 07 May 2012 11:42:03 GMT

Aeterna Zentaris Plans to Continue Phase 3 Study in Multiple Myeloma Keryx to Receive Royalty in Exchange for Development Data and Intellectual Property NEW YORK, May 7, 2012 /PRNewswire via COMTEX/ --Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the Company and Aeterna Zentaris Inc. have executed a License Termination and Technology Transfer Agreement, whereby the KRX-0401 (perifosine) license agreement has been terminated and all license rights have reverted back to Aeterna Zentaris. In exchange for the transfer of the U.S. Investigational New Drug Application, development data, intellectual property and contracts to Aeterna Zentaris, Aeterna Zentaris has assumed ...

Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical

Mon, 23 Apr 2012 12:39:49 GMT

NEW YORK, April 23, 2012 /PRNewswire via COMTEX/ --Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis. This study is part of an ongoing Phase 3 program for ferric citrate in Japan for the treatment of hyperphosphatemia. The Phase 3 study, conducted in Japan, was an open-label, randomized study evaluating the efficacy and safety of ferric citrate against an active control, sevelamer hydrochloride, over 12 we...

Keryx Biopharmaceuticals Announces Top-Line Data from the Perifosine (KRX-0401) X-PECT Phase 3 Clinical Trial

Mon, 02 Apr 2012 11:00:26 GMT

NEW YORK, April 2, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported today that the Phase 3 "X-PECT" (Xeloda® + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo. This Phase 3 trial was conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. 468 patients at sixty-five U.S. sites participated in this study. Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are all extremely disappointed with the resu...

Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results

Wed, 29 Feb 2012 21:30:35 GMT

Keryx to Host Investor Conference Call on Thursday, March 1, 2012 at 8:30am EST NEW YORK, Feb. 29, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2011. At December 31, 2011, the Company had cash, cash equivalents, interest receivable, and investment securities of $39.5 million, as compared to $28.5 million at December 31, 2010. The net loss for the fou...

Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results

Tue, 28 Feb 2012 21:30:21 GMT

Investor Conference Call to be held Thursday, March 1, 2012 at 8:30am EST NEW YORK, Feb. 28, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced that a conference call will be held on Thursday, March 1, 2012, at 8:30 a.m. EST to discuss the Company's fourth quarter and year-end 2011 financial results and business outlook for 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host the call. In order to participate in the conference call, please call 1-877-869-3847...